Errata - English

Line 1 of Vitamin A, Method 1/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 16 of Sample solution: Change
Dilute a 10-mL volume of this solution
to:
Sample solution: Dilute a 10-mL volume of the Sample stock solution
AND
Line 2 of Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution: Change
Proceed as directed for the Sample solution
to:
Proceed as directed for the Sample stock solution
AND
Line 1 of Vitamin E, Method 1/Sample solution: Change
Proceed as directed for the Sample solution
to:
Proceed as directed for the Sample stock solution
AND
Line 2 of Phytonadione, Method 1/Sample solution: Change
retained as specified in the directions for Sample solution
to:
retained as specified in the directions for Sample stock solution

Line 1 of Vitamin A, Method 1/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 23 of Vitamin A, Method 1/Sample solution: Change
Dilute a volume of this solution
to:
Sample solution: Dilute a volume of the Sample stock solution
AND
Line 2 of Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution:Change
prepared as directed for the Sample solution
to:
prepared as directed for the Sample stock solution
AND
Line 2 of Vitamin E, Method 1/Sample solution:Change
prepared as directed for the Sample solution
to:
prepared as directed for the Sample stock solution
AND
Line 2 of Phytonadione:Change
prepared as directed for the Sample solution
to:
prepared as directed for the Sample stock solution

Line 1 of Dissolution <711>/Analysis:Change
Determine the labeled amount of acetaminophen
to:
Determine the percentage of the labeled amount of acetaminophen
AND
In the Calculate statement of Uniformity of Dosage Units <905>/Procedure for content uniformity/Analysis: Change
Calculate the quantity, in mg, of the labeled amount of codeine phosphate
to:
Calculate the quantity, in mg, of codeine phosphate

Line 1 of Sample solution: Change
Transfer 3.0 mL of the clear filtrate, reserved from the Assay, to a 100-mL volumetric flask.
to:
Sample stock solution: Dilute the clear filtrate, reserved from the Assay, with water to obtain a solution containing about 160 µg/mL of potassium citrate monohydrate.
Sample solution: Transfer 3.0 mL of the Sample stock solution to a 100-mL volumetric flask.

Line 1 of the variable definition list: Change
r_U = peak response of any impurity from the Sample solution
r_S = peak response of rocuronium bromide from the Dilute standard solution
to:
r_U = peak response of 2-propanol from the Sample solution
r_S = peak response of 2-propanol from the Dilute standard solution

Line 1 of Vitamin A, Method 1/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 23 of Sample solution: Change
Dilute a volume of this solution
to:
Sample solution: Dilute a volume of the Sample stock solution
AND
Line 1 of Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution:Change
Proceed as directed for the Sample solution
to:
Proceed as directed for the Sample stock solution
AND
Line 1 of Vitamin E, Method 1/Sample solution: Change
Proceed as directed for the Sample solution
to:
Proceed as directed for the Sample stock solution
AND
Line 2 of Phytonadione/Sample solution:Change
in the directions for the Sample solution
to:
in the directions for the Sample stock solution

Line 1 of Vitamin A/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 21 of Sample solution: Change
Further dilute this solution
to:
Sample solution: Dilute the Sample stock solution
AND
Line 2 of Vitamin D/Sample solution: Change
as directed for the Sample solution
to:
as directed for the Sample stock solution
AND
Line 2 of Vitamin E/Sample solution: Change
prepared as directed for the Sample solution
to:
prepared as directed for the Sample stock solution
AND
Line 2 of Phytonadione (Vitamin K₁):Change
as directed for the Sample solution
to:
as directed for the Sample stock solution
AND
Line 2 of Beta Carotene/Sample solution: Change
as directed for the Sample solution
to:
as directed for the Sample stock solution

Line 1 of Vitamin A, Method 1/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 16 of Sample solution: Change
Dilute a 10-mL volume of this solution
to:
Sample solution: Dilute a 10-mL volume of the Sample stock solution
AND
Line 2 of Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution: Change
prepared as directed for the Sample solution
to:
prepared as directed for the Sample stock solution
AND
Line 2 of Vitamin E, Method 1/Sample solution: Change
prepared as directed for the Sample solution
to:
prepared as directed for the Sample stock solution
AND
Line 2 of Phytonadione, Method 1/Sample solution: Change
prepared as directed for the Sample solution
to:
prepared as directed for the Sample stock solution

Line 1 of Dissolution <711>/Analysis:Change
Determine the labeled amount of acetaminophen
to:
Determine the percentage of the labeled amount of acetaminophen
AND
In the second Calculate statement in Uniformity of Dosage Units <905>/Procedure for content uniformity/Analysis: Change
Calculate the quantity, in mg/mL, of the labeled amount of codeine phosphate
to:
Calculate the quantity, in mg, of codeine phosphate

The version of the Timolol Maleate monograph which appeared in the Second Supplement to USP 40–NF 35 did not include the revisions approved in the version appearing in the First Supplement to USP 40–NF 35. The version appearing in the First Supplement should be used. The file as it should have appeared in the Second Supplement is attached to the compendial notice found at http://www.uspnf.com/notices/second-supplement-usp-40-nf-35-online-timolol-maleate.

Line 1 of Vitamin A, Method 1/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 23 of Sample solution: Change
Dilute a volume of this solution
to:
Sample solution: Dilute a volume of the Sample stock solution
AND
Line 1 of Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution:Change
Proceed as directed for the Sample solution
to:
Proceed as directed for the Sample stock solution
AND
Line 1 of Vitamin E, Method 1/Sample solution: Change
Proceed as directed for the Sample solution
to:
Proceed as directed for the Sample stock solution
AND
Line 1 of Phytonadione/Sample solution:Change
Proceed as directed for the Sample solution
to:
Proceed as directed for the Sample stock solution

Line 1 of Vitamin A, Method 1/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 16 of Sample solution: Change
Dilute a 10-mL volume of this solution
to:
Sample solution: Dilute a 10-mL volume of the Sample stock solution
AND
Line 1 of Cholecalciferol or Ergocalciferol (Vitamin D), Method 1/Sample solution: Change
Proceed as directed for the Sample solution
to:
Proceed as directed for the Sample stock solution
AND
Line 1 of Vitamin E, Method 1/Sample solution: Change
Proceed as directed for the Sample solution
to:
Proceed as directed for the Sample stock solution
AND
Line 2 of Phytonadione, Method 1/Sample solution: Change
retained as specified in the directions for the Sample solution
to:
retained as specified in the directions for the Sample stock solution

Line 1 of Vitamin A/Sample solution: Change
Sample solution
to:
Sample stock solution
AND
Line 15 of Sample solution: Change
Further dilute this solution
to:
Sample solution: Dilute the Sample stock solution
AND
Line 2 of Vitamin D/Sample solution: Change
as directed for the Sample solution
to:
as directed for the Sample stock solution
AND
Line 2 of Vitamin E/Sample solution: Change
prepared as directed for the Sample solution
to:
prepared as directed for the Sample stock solution
AND
Line 2 of Phytonadione (Vitamin K₁):Change
as directed for the Sample solution
to:
as directed for the Sample stock solution
AND
Line 2 of Beta Carotene/Sample solution: Change
as directed for the Sample solution
to:
as directed for the Sample stock solution

Line 1 of Standard solution: Change
Standard solution: 1.0 mg/mL each of five polyethylene glycol standards with molecular weights of 1000,2000, 3000, 4000, and 6000 g/mol (Da) in Mobilephase. Pass a portion of the solution
to:
Standard solutions: Prepare 1.0 mg/mL each of five polyethylene glycol standards with molecular weights of 1000,2000, 3000, 4000, and 6000 g/mol (Da) in Mobilephase separately in five individual flasks. Pass a portion of each solution
AND
Line 1 of Analysis/Samples: Change
Standard solution and Sample solution
to:
Standard solutions and Sample solution
AND
Line 3 of Analysis: Change
Separately inject equal volumes of the Standard solution
to:
Separately inject equal volumes of the Standard solutions

Line 1 of Sample solution: Change
1 mg/mL of Oral Suspension in Diluent
to:
Nominally 1 mg/mL of phenytoin prepared as follows. Weigh and transfer a suitable volume of Oral Suspension to an appropriate volumetric flask. Add methanol to about 20% of the final flask volume and dissolve. Dilute with Diluent to volume. Dissolve with the aid of sonication, if necessary.

Footnote c of Table 2: Change
(2aR,4R,4aS,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4, 9,11,12,12b-pentahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca[3,4]benz[1,2-b]oxet-5,6-dione 12b-acetate, 12-benzoate, 9-ester with (2R,3S)-N-formyl-3-phenylisoserine.
to:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)‐12b‐Acetoxy‐9‐(((2R,3S)‐3‐formamido‐2‐hydroxy‐3‐phenylpropanoyl)oxy)‐4,6,11‐trihydroxy‐4a,8,13,13‐tetramethyl‐5‐oxo‐2a,3,4,4a,5,6,9,10,11,12,12a,12b‐dodecahydro‐1H‐7,11‐methanocyclodeca[3,4]benzo[1,2‐b]oxet-12‐yl benzoate.
AND
Footnote d of Table 2: Change
(2aR,4R,4aS,6R,9S,11S,12S,12aR,12bS)-6-{[(2,2-Dichloroethoxy)carbonyl]oxy}-1,2a,3,4,4a,6,9,10,11,12,12a,12b-dodecahydro-4,9,11,12,12b-pentahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca[3,4]benz[1,2-b)oxet-5-one 12b-acetate, 12-benzoate, 9-ester with (2R,3S)-N-tert-butoxycarbonyl-e-phenylisoserine.
to:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)‐6‐{[(2,2‐Dichloroethoxy)carbonyl]oxy}‐1,2a,3,4,4a,6,9,10,11,12,12a,12b‐dodecahydro‐4,9,11,12,12b‐pentahydroxy‐4a,8,13,13‐tetramethyl‐7,11‐methano‐5H‐cyclodeca[3,4]benz[1,2‐b]oxet‐5‐one 12b‐acetate, 12‐benzoate, 9‐ester with (2R,3S)‐N‐tert-butoxycarbonyl‐3‐phenylisoserine.

Line 2: Change
proceed as directed in the test for Delivered Dose Uniformity in Metered-Dose Inhalers and Dry Powder Inhalers, as described in <601>,
to:
proceed as directed in Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests <601>, A. Delivered-Dose Uniformity/A.2 Inhalation Aerosols and Inhalation Sprays and A.4 Inhalation Powders,
AND
Line 4: Delete
Unless otherwise stated in the individual monograph, apply the acceptance criteria for Metered-Dose Inhalers and Dry Powder Inhalers as described in <601>.

Change
Buffer, Mobile phase, Diluent, and Sample solution: Prepare as directed in the Assay.
to:
Buffer, Mobile phase, and Diluent: Prepare as directed in the Assay.
AND
Add
Sample solution: Use the Sample stock solution as directed in the Assay.